Lilly is now selling $12.9 billion of GLP-1 drugs every three months and expects to sell even more
Eli Lilly's tirzepatide franchise generated $12.9 billion in quarterly sales, with expectations for further growth.
impact+0.70
sentiment+0.80
n=3
lilly is now selling $12.9 billion of its glp-1 drugs every three months. that's the tirzepatide franchise — mounjaro and zepbound — and the company says the next quarter will be even bigger. the drugs treat diabetes and obesity, and demand keeps climbing. lilly didn't give a specific forecast for the current quarter, but the trajectory is clear: these are now among the best-selling drugs in history. the $12.9 billion figure covers the most recent three-month period.
read at marketwatch_top →